FRA:UKJ (Australia)
Â
Business Description
Opthea Ltd
NAICS : 325412
SIC : 2834
Compare
Compare
Traded in other countries / regions
OPT.AustraliaUKJ.GermanyOPT.USA Description
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused primarily on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.8 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 3.89 | |||||
| Beneish M-Score | -6.08 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -100 | |||||
| 3-Year EBITDA Growth Rate | -34 | |||||
| 3-Year EPS without NRI Growth Rate | -59.9 | |||||
| 3-Year FCF Growth Rate | -40.1 | |||||
| 3-Year Book Growth Rate | 15.5 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 79.09 | |||||
| 9-Day RSI | 71.48 | |||||
| 14-Day RSI | 63.76 | |||||
| 6-1 Month Momentum % | -33.33 | |||||
| 12-1 Month Momentum % | -13.39 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.97 | |||||
| Quick Ratio | 4.97 | |||||
| Cash Ratio | 3.71 | |||||
| Days Sales Outstanding | 2207.92 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -12.2 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -108421.14 | |||||
| Net Margin % | -104246.74 | |||||
| ROE % | -102.08 | |||||
| ROA % | -93.85 | |||||
| ROIC % | -824.33 | |||||
| ROC (Joel Greenblatt) % | -1437.51 | |||||
| ROCE % | -106.14 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 4.88 | |||||
| Price-to-Tangible-Book | 4.83 | |||||
| EV-to-EBIT | -1.89 | |||||
| EV-to-EBITDA | -1.89 | |||||
| EV-to-Revenue | 2051.08 | |||||
| EV-to-Forward-Revenue | 902.02 | |||||
| EV-to-FCF | -2.59 | |||||
| Price-to-Net-Current-Asset-Value | 4.83 | |||||
| Price-to-Net-Cash | 7.25 | |||||
| Earnings Yield (Greenblatt) % | -52.8 |
